Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
3 ASX Stocks Rise as Revenue Growth, Stronger Profits and Higher Production Boost Market Sentiment
Source: Kapitales Research
Highlights:
A healthcare business reported a 44% increase in product revenue and an 85% improvement in operating cash spend.
Stronger profitability and cash generation supported improved annual results and higher shareholder returns for an infrastructure services provider.
Quarterly production increased 9%, while sales revenue climbed 41% to a record level for an energy producer.
Introduction
Several ASX-listed companies attracted investor attention on 21 October 2026, supported by business updates highlighting revenue growth, improved financial performance and operational progress. Developments across healthcare, infrastructure services and energy provided fresh information for investors assessing company performance and future prospects.
Stocks in Focus:
Mesoblast Limited (ASX: MSB) shares traded at AU$1.860, up AU$0.100 or 5.681%.
Service Stream Limited (ASX: SSM) shares traded at AU$2.250, up AU$0.120 or 5.633%.
Beach Energy Limited (ASX: BPT) shares traded at AU$0.960, up AU$0.049 or 5.494%.
Healthcare Revenue Growth and Lower Cash Spend
Mesoblast Limited announced on 16 October 2026 that net revenue from sales of Ryoncil increased 44% to US$28 million in the first fiscal quarter of 2026, compared with US$19 million in the prior-year period. Net operating cash spend fell 85% to US$2.3 million from US$14.9 million, while the company held US$99 million in cash at 30 September 2026. September also recorded the highest monthly number of new patient starts, following the expected seasonal slowdown in July and August. The company said it plans to increase Ryoncil adoption across its 54 onboarded sites while maintaining disciplined spending on manufacturing and late-stage clinical programmes. The figures remain based on preliminary estimates and are subject to customary closing and audit procedures.
Improved Profitability and Shareholder Returns
Service Stream Limited’s Managing Director’s presentation, dated 21 October 2026, outlined stronger FY26 financial performance and progress in diversifying its operations. Revenue reached AU$2.475 billion, up 2.3% from the previous corresponding period, while EBITDA from operations increased 11.8% to AU$163.4 million. Adjusted net profit after tax rose 18.4% to AU$81.1 million, and the company reported net cash of AU$80.7 million. Its group EBITDA margin improved by 60 basis points to 6.6%, while the utility margin reached 5.8%. The presentation also highlighted AU$8.2 billion in work in hand, entry into the defence sector and an 18.2% increase in the annual dividend to 6.5 cents per share.
Higher Production and Record Quarterly Revenue
Beach Energy Limited reported on 21 October 2026 that production rose 9% quarter-on-quarter to 5.4 million barrels of oil equivalent in the first quarter of FY27. Sales revenue increased 41% to AU$565 million, the highest quarterly revenue recorded by the company. Improved output from the Otway, Western Flank and Bass Basin operations contributed to the production increase. The average realised gas price rose 7% to AU$11.9 per gigajoule, supported by marketing and portfolio optimisation, while oil sales benefited from price premiums. The company maintained its FY27 production guidance of 19.5–23.0 million barrels of oil equivalent and capital expenditure guidance of AU$600–700 million. Completion of the Waitsia shutdown and Equinox campaign also reduced uncertainty around future cash flow.
Conclusion
The three announcements highlighted different sources of business momentum, from healthcare product sales and lower cash spending to stronger service-sector profitability and increased energy production. Investors will continue to monitor execution, future operating results and the companies’ ability to sustain these improvements.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
3 ASX Stocks Rise as Revenue Growth, Stronger Profits and Higher Production Boost Market Sentiment
Highlights:
Introduction
Several ASX-listed companies attracted investor attention on 21 October 2026, supported by business updates highlighting revenue growth, improved financial performance and operational progress. Developments across healthcare, infrastructure services and energy provided fresh information for investors assessing company performance and future prospects.
Stocks in Focus:
Healthcare Revenue Growth and Lower Cash Spend
Mesoblast Limited announced on 16 October 2026 that net revenue from sales of Ryoncil increased 44% to US$28 million in the first fiscal quarter of 2026, compared with US$19 million in the prior-year period. Net operating cash spend fell 85% to US$2.3 million from US$14.9 million, while the company held US$99 million in cash at 30 September 2026. September also recorded the highest monthly number of new patient starts, following the expected seasonal slowdown in July and August. The company said it plans to increase Ryoncil adoption across its 54 onboarded sites while maintaining disciplined spending on manufacturing and late-stage clinical programmes. The figures remain based on preliminary estimates and are subject to customary closing and audit procedures.
Improved Profitability and Shareholder Returns
Service Stream Limited’s Managing Director’s presentation, dated 21 October 2026, outlined stronger FY26 financial performance and progress in diversifying its operations. Revenue reached AU$2.475 billion, up 2.3% from the previous corresponding period, while EBITDA from operations increased 11.8% to AU$163.4 million. Adjusted net profit after tax rose 18.4% to AU$81.1 million, and the company reported net cash of AU$80.7 million. Its group EBITDA margin improved by 60 basis points to 6.6%, while the utility margin reached 5.8%. The presentation also highlighted AU$8.2 billion in work in hand, entry into the defence sector and an 18.2% increase in the annual dividend to 6.5 cents per share.
Higher Production and Record Quarterly Revenue
Beach Energy Limited reported on 21 October 2026 that production rose 9% quarter-on-quarter to 5.4 million barrels of oil equivalent in the first quarter of FY27. Sales revenue increased 41% to AU$565 million, the highest quarterly revenue recorded by the company. Improved output from the Otway, Western Flank and Bass Basin operations contributed to the production increase. The average realised gas price rose 7% to AU$11.9 per gigajoule, supported by marketing and portfolio optimisation, while oil sales benefited from price premiums. The company maintained its FY27 production guidance of 19.5–23.0 million barrels of oil equivalent and capital expenditure guidance of AU$600–700 million. Completion of the Waitsia shutdown and Equinox campaign also reduced uncertainty around future cash flow.
Conclusion
The three announcements highlighted different sources of business momentum, from healthcare product sales and lower cash spending to stronger service-sector profitability and increased energy production. Investors will continue to monitor execution, future operating results and the companies’ ability to sustain these improvements.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au